Zobrazeno 1 - 10
of 6 791
pro vyhledávání: '"parp inhibitor"'
Autor:
Christoph Rogmans, Jan Dittrich, Emily Hamm, Jörg Paul Weimer, David Holthaus, Norbert Arnold, Inken Flörkemeier, Nicolai Maass, Peer Jansen, Astrid Dempfle, Dirk O. Bauerschlag, Nina Hedemann
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Acquired or de novo resistance to poly (ADP-ribose) polymerase inhibitors (PARPi) is a major challenge to ovarian cancer treatment. Therefore, strategies to overcome PARPi resistance are critical to improve prognosis. The purpose of this stu
Externí odkaz:
https://doaj.org/article/4291c4464e794268896575de7315d9cc
Autor:
Hyeong In Ha, Hyung Joon Yoon, Changho Song, Eun Taeg Kim, Dong-Soo Suh, Ki Hyung Kim, Yong Jin Na, Yong Jung Song
Publikováno v:
Current Oncology, Vol 31, Iss 11, Pp 6711-6722 (2024)
Purpose: In this study, we aimed to retrospectively investigate the real-world clinical efficacy and adverse events of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in real-world clinical practice among patients with newly dia
Externí odkaz:
https://doaj.org/article/5ce1ebf81db444ce873ff71f9a0433f7
Autor:
Jiayi Li, Ziqi Jia, Lin Dong, Heng Cao, Yansong Huang, Hengyi Xu, Zhixuan Xie, Yiwen Jiang, Xiang Wang, Jiaqi Liu
Publikováno v:
Biomarker Research, Vol 12, Iss 1, Pp 1-32 (2024)
Abstract DNA damage response (DDR) deficiency has been one of the emerging targets in treating breast cancer in recent years. On the one hand, DDR coordinates cell cycle and signal transduction, whose dysfunction may lead to cell apoptosis, genomic i
Externí odkaz:
https://doaj.org/article/022406c0024840c49cd64f88da50a85b
Autor:
Yifan Tai, Angela Chow, Seoyoung Han, Courtney Coker, Wanchao Ma, Yifan Gu, Valeria Estrada Navarro, Manoj Kandpal, Hanina Hibshoosh, Kevin Kalinsky, Katia Manova-Todorova, Anton Safonov, Elaine M Walsh, Mark Robson, Larry Norton, Richard Baer, Taha Merghoub, Anup K Biswas, Swarnali Acharyya
Publikováno v:
EMBO Molecular Medicine, Vol 16, Iss 8, Pp 1957-1980 (2024)
Abstract Acquired resistance to PARP inhibitors (PARPi) remains a treatment challenge for BRCA1/2-mutant breast cancer that drastically shortens patient survival. Although several resistance mechanisms have been identified, none have been successfull
Externí odkaz:
https://doaj.org/article/2b7acab7d8864163a88c5615d51c25ce
Autor:
Takehiro Nakao, Kenichi Harano, Masashi Wakabayashi, Yoichi Naito, Hiroshi Tanabe, Toru Mukohara
Publikováno v:
Gynecologic Oncology Reports, Vol 55, Iss , Pp 101482- (2024)
Objective: Platinum-free interval (PFI) is the period from the end of platinum-based chemotherapy to the date of recurrence. If the PFI is > 6 months, a platinum-based chemotherapy rechallenge is considered; however, its efficacy after poly adenosine
Externí odkaz:
https://doaj.org/article/531ab3d12ed3433ea0a6a2a65cf6a74f
Autor:
Todd Tillmanns, Amal Masri, Chelsea Stewart, Dana Chase, Anthony Karnezis, Lee-may Chen, Renata Urban
Publikováno v:
Gynecologic Oncology Reports, Vol 55, Iss , Pp 101462- (2024)
In February of 2024, the Society of Gynecologic Oncology (SGO) hosted a journal club focused on new treatment options for the management of advanced and metastatic endometrial cancer. This clinical commentary is intended to provide a summary report o
Externí odkaz:
https://doaj.org/article/fa419a628fa04ec4a53671c85880bd42
Publikováno v:
Journal of Men's Health, Vol 20, Iss 3, Pp 113-120 (2024)
Prostate cancer (PC) has risen to become the second most common neoplasm in men, trailing only lung cancer. Individuals with advanced prostate cancer, particularly those who are resistant to androgen deprivation therapy (ADT), also known as castratio
Externí odkaz:
https://doaj.org/article/660c825b3f874bdd85e2062371d155da
Publikováno v:
Cancer Nanotechnology, Vol 15, Iss 1, Pp 1-16 (2024)
Abstract Background The addition of the cyclin dependent kinase inhibitor (CDKi) dinaciclib to Poly-(ADP-ribose) polymerase inhibitor (PARPi) therapy is a strategy to overcome resistance to PARPi in tumors that exhibit homologous recombination (HR) d
Externí odkaz:
https://doaj.org/article/bcb38076fd6e4bebba02ff716de87352
Autor:
Mark S. Kim, Deanna Glassman, Katelyn F. Handley, Adrian Lankenau Ahumada, Nicholas B. Jennings, Emine Bayraktar, Katherine Foster, Robiya Joseph, Sanghoon Lee, Robert L. Coleman, Anil K. Sood
Publikováno v:
Cancer Medicine, Vol 13, Iss 15, Pp n/a-n/a (2024)
Abstract Background GP‐2250, a novel analog of taurultam (TRLT), has emerged as a potent anti‐neoplastic drug; however, the mechanisms underlying its effects are not well understood. Here, we investigated the mechanism of action and the biologica
Externí odkaz:
https://doaj.org/article/8fee05e54a2146f8a9853a7f0ad7e50c
Autor:
Qiaodan Deng, Jiankun Qiang, Cuicui Liu, Jiajun Ding, Juchuanli Tu, Xueyan He, Jie Xia, Xilei Peng, Siqin Li, Xian Chen, Wei Ma, Lu Zhang, Yi‐Zhou Jiang, Zhi‐Ming Shao, Ceshi Chen, Suling Liu, Jiahui Xu, Lixing Zhang
Publikováno v:
Advanced Science, Vol 11, Iss 29, Pp n/a-n/a (2024)
Abstract Breast tumor‐initiating cells (BTICs) of triple‐negative breast cancer (TNBC) tissues actively repair DNA and are resistant to treatments including chemotherapy, radiotherapy, and targeted therapy. Herein, it is found that a previously r
Externí odkaz:
https://doaj.org/article/1e3b009041f14a21a1f006ddc2dac957